If we exclude the select few patients that have microsatellite unstable tumours and that might benefit from immunotherapy, targeted agents commonly used in colorectal cancer treatment fall within 2 main categories: the anti-EGFR or anti-VEGF pathway. This evidence concerns the gene VEGFA and neoplasm.